The Effects of Rifaximin Therapy in Irritable Bowel Syndrome

NCT ID: NCT02009618

Last Updated: 2013-12-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 500 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2013-10-31

Brief Summary

To evaluate the efficacy of Rifaximin therapy started prior to completion of advanced examination procedure (before colonoscopy) of patients pre-diagnosed with irritable bowel syndrome, and implement it into clinical practice.

Detailed Description

Irritable Bowel Syndrome(IBS) is a chronic relapsing disorder with unknown etiology characterized by abdominal pain and bowel habit changes without an organic pathology. Pathophysiology is not fully understood, bacterial overgrowth is one of the reasons. Because of that, use of drugs effective on the gut flora has been raised; Rifaximin is one of them. This study investigated the effectiveness of Rifaximin on IBS.

This randomized, double-blinded, controlled study began with 500 patients(144 of them removed because of incompliance). Patients those without organic bowel pathology and whom meet the Rome-III criteria, aged between 19-50 yo were enrolled in the study. Patients with known Rifaximin allergy, lactose intolerance, and those having treated for IBS whit in last 1 month as well as those with alarm symptoms (melena, fever, weight loss, anemia, rectal bleeding) were excluded. After routine biochemistry, blood count, and stool tests, Rifaximin tablet was given to a group as 1200 mg. daily in 3 divided doses, placebo tablet was given to another group in same doses for 10 days. Improvement in symptoms were scored and recorded on 10.day, 3. and 6.week. In addition to descriptive statistical methods(mean±SD), Student's-T and Mann-Whitney U-tests were used for comparison of quantitative data, chi-square and McNemar tests were used for comparison of qualitative data. Significance was accepted if p <0.05.

Conditions

IBS

Keywords

IBS; Rifaximin

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Irritable bowel syndrome patients

placebo tablet was given to another group in same doses for 10 days

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

Rifaximin

Irritable bowel syndrome patients

Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days

Group Type: EXPERIMENTAL

Rifaximin

Intervention Type: DRUG

Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.

Interventions

Rifaximin

Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.

Intervention Type: DRUG

placebo

Intervention Type: DRUG

Other Intervention Names

Colidur 200 mg tablets

Eligibility Criteria

Inclusion Criteria

• Patients between the ages of 18 and 50 years without alarm symptoms, who were examined at the Gastroenterology Clinic, without endoscopic assessment, due to complaints of Irritable Bowel Syndrome, and pre-diagnosed with Irritable Bowel Syndrome according to the Rome III criteria, will be included in the study.

Exclusion Criteria

1. are under the age of 18 years,

2. are allergic to Rifaximin,

3. are pregnant and lactating,

4. have documented diseases of the gastrointestinal system (such as gastric and duodenal ulcers, gastric cancer, small intestine and colon cancer, inflammatory bowel disease [Crohn's and Ulcerative Colitis], gastroparesis, chronic intestinal ischemia, etc.),

5. have (describe) documented diseases of the pancreas, biliary tract, and liver (such as pancreatitis, biliary colic pain associated with gallstones, acute cholecystitis, choledochal stone, hepatitis, hepatobiliary cancers, etc.),

6. have previously undergone major abdominal surgery,

7. have a systemic disease (such as collagen tissue disorders, kidney dysfunction, systemic infection, etc.),

8. have an identified psychiatric disorder,

and/or

9. consume alcohol excessively

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bezmialem Vakif University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hakan Şentürk, Prof

Role: STUDY_DIRECTOR

Bezmialem Vakıf University, Gastroenterology Clinic

Locations

Bezmialem Vakıf University, Gastroenterology Clinic

Istanbul, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

References

Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002 May;122(6):1701-14. doi: 10.1053/gast.2002.33741.

Reference Type: BACKGROUND

PMID: 12016433 (View on PubMed)

Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:1-9. doi: 10.1111/j.1365-2036.2004.02036.x.

Reference Type: BACKGROUND

PMID: 15335408 (View on PubMed)

Talley NJ. Irritable bowel syndrome. Intern Med J. 2006 Nov;36(11):724-8. doi: 10.1111/j.1445-5994.2006.01217.x.

Reference Type: BACKGROUND

PMID: 17040359 (View on PubMed)

Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-42.

Reference Type: BACKGROUND

PMID: 18217406 (View on PubMed)

Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am. 2005 Jun;34(2):319-35, viii. doi: 10.1016/j.gtc.2005.02.002.

Reference Type: RESULT

PMID: 15862938 (View on PubMed)

Other Identifiers

27.1.2013 / 1

Identifier Type: -

Identifier Source: org_study_id